Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Research from Yale University, Medical Department yields new findings on angiogenesis
June 30th, 2009
According to recent research from the United States, "Vascular endothelial growth factor (VEGF) has been implicated in tumor angiogenesis and is a potential therapeutic target in prostatic adenocarcinoma (PrCa). Immunohistochemical (IHC) analysis has been used to demonstrate VEGF expression in PrCa, and in various other tumors including breast carcinoma, renal cell carcinoma, hepatocellular carcinoma, and gliomas." "Prior Studies have reported markedly varied VEGF expression in benign prostatic hyperplasia (0% to 100%,) and PrCa (40% to 100%). The objective of this Study was to Measure VEGF expression in PrCa specimens, using, IHC analysis with antibodies from different...
Source: Cancer Weekly (2009-06-30)
|
